Oncology Reviews http://oncologyreviews.org/index.php/or <p><strong>Oncology Reviews</strong> is an Open Access, peer-reviewed, international journal that publishes authoritative state-of-the-art reviews on preclinical and clinical aspects of oncology. <br>The journal was previously published by Springer Italy; since 2012 Oncology Reviews passed to <em>PAGEPress</em>.&nbsp;The journal will provide up-to-date information on the latest achievements in different fields of oncology for both practising clinicians and basic researchers. Oncology Reviews aims at being international in scope and readership, as reflected also by its Editorial Board, gathering the world leading experts in both pre-clinical research and everyday clinical practice. The journal is open for publication of supplements, monothematic issues and for publishing abstracts of scientific meetings; conditions can be obtained from the Editor-in-Chief or the publisher.<br><br><strong>Oncology Reviews</strong> is completely free, as it is supported by private funds.</p> PAGEPress Scientific Publications, Pavia, Italy en-US Oncology Reviews 1970-5557 <p>PAGEPress has chosen to apply the&nbsp;<a href="http://creativecommons.org/licenses/by-nc/4.0/" target="_blank" rel="noopener">Creative Commons Attribution NonCommercial 4.0 International License</a>&nbsp;(CC BY-NC 4.0) to all manuscripts to be published.&nbsp;<br><br>An Open Access Publication is one that meets the following two conditions:<br><br>1. The author(s) and copyright holder(s) grant(s) to all users a free, irrevocable, worldwide, perpetual right of access to, and a license to copy, use, distribute, transmit and display the work publicly and to make and distribute derivative works, in any digital medium for any responsible purpose, subject to proper attribution of authorship, as well as the right to make small numbers of printed copies for their personal use.<br>2. A complete version of the work and all supplemental materials, including a copy of the permission as stated above, in a suitable standard electronic format is deposited immediately upon initial publication in at least one online repository that is supported by an academic institution, scholarly society, government agency, or other well-established organization that seeks to enable open access, unrestricted distribution, interoperability, and long-term archiving.<br><br>Authors who publish with this journal agree to the following terms: 1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. 2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. 3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.</p> Punica granatum (Pomegranate) activity in health promotion and cancer prevention http://oncologyreviews.org/index.php/or/article/view/345 Cancer has become one of the most fatal diseases in most countries. In spite of the medical care developing, cancer still remains a significant problem. The majority of the cancers are resistant to treatment. Thus, the research for novel, more efficient and less side effect treatment methods continues. Pomegranate contains strong antioxidant activity, with potential health interests. Research concern in pomegranate is increasing because of their anticancer potential due to possess rich in polyphenols. We highlight the pomegranate potential health benefits and mechanism of cancer progression inhibition. Pomegranate has indicated antiproliferative, anti-metastatic and anti-invasive effects on different cancer cell line <em>in vitro,</em> <em>in vivo</em> and clinical trial. The aim of this review is to evaluate functional properties and the medical benifits of pomegranate against various cancer diseases. In addition, pomegranate properties in <em>in vitro</em> and <em>in vivo</em> experimental human and animal clinical trials and its future use are explored. The available data suggest that <em>Punica granatum</em> (pomegranate) might be used in the control and potential therapeutic for some disease conditions and benefits human health status. This review summarizes <em>in vitro</em>, <em>in vivo</em> and clinical trial studies highlighting the pomegranate role in prevent and treatment of breast, prostate, lung, colon, skin and hepatocellular cell cancers. Shahindokht Bassiri-Jahromi ##submission.copyrightStatement## http://creativecommons.org/licenses/by-nc/4.0 2018-01-30 2018-01-30 12 1 10.4081/oncol.2018.345 The role of pemetrexed in recurrent epithelial ovarian cancer: a scoping review http://oncologyreviews.org/index.php/or/article/view/346 <p>Ovarian cancer is the leading cause of mortality among gynecologic malignancies, with most cases diagnosed at an advanced stage. Despite an initial response, most develop a recurrence and subsequent resistance to standard therapies. Pemetrexed (Alimta<sup>TM</sup>) is a new generation multi-targeted antifolate initially approved for the treatment of malignant pleural mesothelioma. In recent years, it has shown promise in the treatment of recurrent epithelial ovarian cancer. In this review, we outline the current literature and discuss the future of pemetrexed in the setting of recurrent epithelial ovarian cancer.</p> Michael Roche Laura Parisi Linda Li Amy Knehans Rebecca Phaeton Joshua P. Kesterson ##submission.copyrightStatement## http://creativecommons.org/licenses/by-nc/4.0 2018-03-21 2018-03-21 12 1 10.4081/oncol.2018.346